Metastatic Breast Cancer Treatment Planning
NCT03127332 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2019-01-31
Summary
The overarching objective of this study is to close clinical knowledge and performance gaps by providing oncology clinicians with the latest advances and emerging research in the evidence-based and personalized treatment of metastatic breast cancer patients. In addition, the research team seeks to meet quality measures relevant to value-based care delivery through IT infrastructure and clinical workflow processes. The research team also hopes to gain insights into clinician practice patterns related to metastatic breast cancer, and the correlation between the reported goals of care for patients with metastatic breast cancer, and the patients' fit/frailty status and treatment decisions.
Conditions
Interventions
- OTHER
-
Carevive CPS
This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
Sponsors & Collaborators
-
Carevive Systems, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-01
- Primary Completion
- 2018-01-31
- Completion
- 2018-01-31
More Related Trials
-
Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca
NCT01074814 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)
NCT01655992 ·Status: TERMINATED ·Phase: PHASE3
-
High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer
NCT00584428 ·Status: COMPLETED ·Phase: NA
-
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
NCT00232505 ·Status: COMPLETED ·Phase: PHASE2
-
Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC
NCT03295552 ·Status: TERMINATED ·Phase: PHASE2
-
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
NCT00153907 ·Status: COMPLETED ·Phase: PHASE1
-
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer
NCT02538471 ·Status: TERMINATED ·Phase: PHASE2
-
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer
NCT00156273 ·Status: COMPLETED
-
Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases
NCT03676257 ·Status: COMPLETED
-
Capecitabine in Women With Operable Breast Cancer
NCT00148720 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
NCT02202746 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
NCT01167192 ·Status: TERMINATED ·Phase: PHASE2
-
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
NCT00102895 ·Status: TERMINATED ·Phase: PHASE2
-
Capecitabine in Treating Patients With Metastatic Breast Cancer
NCT00274768 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
NCT00517361 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692 ·Status: RECRUITING ·Phase: PHASE2
-
Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients
NCT00317603 ·Status: COMPLETED ·Phase: PHASE1
-
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
NCT00483223 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.
NCT06839547 ·Status: NOT_YET_RECRUITING
-
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
NCT05068726 ·Status: TERMINATED
-
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
NCT05932667 ·Status: TERMINATED ·Phase: PHASE2
-
CP-724,714 in Treating Patients With Metastatic Breast Cancer
NCT00055926 ·Status: COMPLETED ·Phase: PHASE1
-
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
NCT01004172 ·Status: COMPLETED ·Phase: PHASE2
-
BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer
NCT02783794 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib In Metastatic Breast Cancer
NCT03344965 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2